- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Corporate Communications
LUX-Breast 1 is an open-label randomized Phase III trial to investigate the efficacy andsafety of oral afatinib* (compound code BIBW 2992) plus vinorelbine compared to trastuzumab plus vinorelbine in patients with metastatic HER2-positive breast cancer who received prior treatment with trastuzumab
* Afatinib (compound code BIBW 2992) is an investigational agent and not approved for the treatment of NSCLC, its effi cacy and safety have not been established.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
